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http://dx.doi.org/10.1016/j.jmii.2014
1684-1182/Copyright ª 2014, TaiwanBackground/purpose: To investigate the characterization of blaOxA-23 gene regions in isolates of
Acinetobacter baumannii from Taizhou Municipal Hospital.
Methods: Fifty-nine non-repetitive, multiresistant (including imipenem-resistant) isolates of A.
baumanniiwere recovered from clinical infections in hospitalized patients from January 2010 to
August 2011 in TaizhouMunicipal Hospital (affiliatedwith TaizhouUniversity) in China. These iso-
lates were genotyped using pulsed-field gel electrophoresis (PFGE). blaOxA-23 b-lactamase and
associated genetic structures were analyzed using polymerase chain reaction (PCR), and recom-
bination plasmids were analyzed by BamHI- or SacI- restriction enzyme digestion; predicted pro-
moter structures of blaOxA-23 genes were determined and compared using protein-protein BLAST
analysis.
Results: Fifteen out of 59 isolates expressing imipenem-resistant A. baumannii clinical isolates
acquired either a blaOxA-23 b-lactamase gene. A new gene cluster (ISAba1-blaOxA-23-AMP) with
three previously identified transposons (Tn2006, Tn2007, and Tn2008) and one previously iden-
tified gene cluster (ISAba1- blaOxA-23) was found in the isolates. Recombination plasmids wereof Clinical Laboratory Medicine, Medical College of Taizhou University Affiliated Taizhou Municipal
of Jiaojiang District in Taizhou, Taizhou 318000, Zhejiang Province, PRC.
of Urology Surgery, Medical College of Taizhou University Affiliated Taizhou Municipal Hospital, 381
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Conclusion: Our results indicate that pattern A was the most prevalent molecular type based on
PFGE, and that different clones might be widespread with a majority of ISAba1-blaOxA-23 clonal
lineages in the 15 PCR positive isolates of A. baumannii in the hospital.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Acinetobacter baumannii, a typical opportunistic path-
ogen, is often involved in nosocomial outbreaks, and
increasingly reported to be resistant to carbapenems.1 The
strains may be linked not only to the production of Ambler
class B metallo-b-lactamases,2 but also to the production of
carbapenem-hydrolyzing class D b-lactamases (CHDLs).3,4
Several studies have shown the geographically widespread
occurrence of three identified multidrug-resistant A. bau-
mannii strains (European clones I, II, and III), suggesting their
clonal relatedness.5,6 According to literature reports, A.
baumannii strains with increasing resistance to carbapenems
have been observed worldwide in the past decade; the main
cause of carbapenem resistance in A. baumannii clinical iso-
lates worldwide is the production of CHDLs, also designated
OXA-type carbapenemases.7 From the different groups of
OXA-type enzymes defined on basis of sequence comparisons,
OXA-23, OXA-24, and OXA-58 (which can be either plasmid- or
chromosomally- encoded) have been most frequently associ-
ated to carbapenem-resistant clinical strains of A. bau-
mannii,1 but OXA-23 has the higher dissemination worldwide.
The b-lactamase OXA-23 was identified first in A. baumannii
fromScotland andwas found to confer transferable imipenem
resistance in A. baumannii.8
Since then, OXA-23 producers have been identified as
the source of nosocomial outbreaks worldwide, including
Brazil, Colombia, the United Kingdom, Korea, Tahiti
(France), and China.9e15 Recently, transposons Tn2006,
Tn2007, and Tn2008 have been described in A. baumannii
isolates from Europe,5 and Tn2008 is a major vehicle car-
rying blaOxA-23 in A. baumannii from China.
16 We describe
here the characterization of the genetic structures in which
blaOxA-23 genes are embedded in A. baumannii clinical iso-
lates obtained in Taizhou Municipal Hospital of China, be-
tween January 2010 and August 2011. These structures
included three transposons (Tn2006, Tn2007, and Tn2008)
and two gene clusters (ISAba1-blaOxA-23-AMP and ISAba1-
blaOxA-23). This is the first report that identifies blaOxA-23
genes harbored by Tn2006, Tn2007, and Tn2008 transposons
in our region.Materials and methods
Bacterial isolates
Fifty-nine non-repetitive, multiresistant (including
imipenem-resistant) isolates of A. baumannii were recov-
ered from clinical infections in hospitalized patients from
January 2010 to August 2011 in Taizhou Municipal Hospital(affiliated with Taizhou University) in China. The patients
were distributed among seven clinical units: intensive care
unit (ICU) (31/59), neurosurgery (12/59), respiratory unit
(6/59), urology surgery (4/59), neurology unit (3/59),
infection unit (2/59), and chest surgery (1/59). The
different bacterial isolates were obtained from sputum
(44/59), blood (11/59), and venous cannula (4/59), and
assigned to the A. calcoaceticus-A. baumannii complex
using a Vitek GNIþ card (bioMerieux, Lyon, France). Species
identification was confirmed by sequence analysis of the
16S-23S rRNA gene intergenic spacer region.17 The different
A. baumannii isolates were designated from Ab1 to Ab59.
Susceptibility testing
The minimum inhibitory concentration (MICs) of seven
representative antimicrobial agents (including imipenem)
for the different isolates, were determined by the Micro-
Scan microdilution panel (Scott, Arizona, USA) broth dilu-
tion method. Escherichia coli ATCC 25922 and Pseudomonas
aeruginosa ATCC 27853 were used as controls. Results were
interpreted according to CLSI 2011 guidelines.18
Pulsed-field gel electrophoresis
DNA was prepared from 15 polymerase chain reaction (PCR)-
positive isolates and cleaved with 40 U ApaI as previously
described.19 Electrophoresis was performed on a 1% agarose
gel in 0.5 M Tris/borate/EDTA buffer on a CHEF-Mapper XA
pulsed-field gel electrophoresis (PFGE) system (Bio-Rad,
Hercules, California, USA) for 22 hours at 14C, with run con-
ditions of6V/cm,apulseangleof120Uandpulse times from5
to 20 seconds. A lDNA ladder (Amersham Biosciences, Pis-
cataway, New Jersey, USA) was used as molecular mass
marker and bands were stained with ethidium bromide
(0.5 mg/L) and photographed under UV light. Band profiles
were interpreted using previous criteria.20
Identification of genetic structures bearing blaOxA-
23 gene in different A. baumannii isolates
One of the aims of this study was to elucidate the mecha-
nism(s) of acquisition and expression of the blaOxA-23 gene
in the A. baumannii isolates recovered from different
hospital areas (Fig. 1). For this purpose, we conducted PCR
amplification following described procedures11,21,22 using
the primers listed in Table 1 in order to identify presump-
tive pre-blaOxA-23, blaOxA-23, blaOxA-23-like, ATPase, ISAba1,
and ISAba4 genes. Total DNA was purified from isolates
generating amplification products and digested with BamHI
Figure 1. Characterization of Acinetobacter baumannii clinical isolates used in this work. The pulsed-field gel electrophoresis
(PFGE) profiles of ApaI-digested genomic DNA of selected clinical A. baumannii isolates are shown on the left. The final positions
and sizes (in kbp) of the molecular markers used are indicated at the top. The figure also includes the assigned PFGE clone (A to E,
right column), and information regarding isolate denomination, date and unit of isolation, minimum inhibitory concentration (MIC)
of imipenem, and the transposon or blaOxA-23 genetic structure identified in the particular isolate. AMPZ AMP-acid ligase gene; M
Z molecular size markers; AM Z ampicillin; AN Z amikacin; CAZ Z ceftazidime; CFS Z cefoperazone/sulbactam;
CFX Z cefoxitin; ICU Z intensive care unit; IMI Z imipenem; LEV Z levofloxacin.
286 D. Wang et al.or SacI. The resulting fragments were ligated into either
BamHI- or SacI-digested pBKCMV plasmid, and transformed
into E. coli DH10B as previously described.23
Transformed bacteria were plated on trypticase soy agar
plates containing amoxicillin (50 mg/mL) and kanamycin
(30 mg/mL), and plasmids obtained from different colonies
selected under these conditions were purified in order to
sequence and analyze the cloned DNA fragments as
described previously.24 The deduced genetic structures
associated with blaOxA-23 gene obtained from these studies
are depicted in Fig. 2. Finally, the cloned DNA fragments
were sequenced and analyzed as described previously.24
Predicted promoter structures of blaOxA-23 genes
and comparison of partial amino acid sequences for
OXA-23-like enzymes
The different promoter regions of blaOxA-23 or blaOxA-23-like
genes identified in the A. baumannii isolates studied here
were obtained by sequence analysis of PCR fragments ob-
tained using primers described in Table 1, and the results
are shown in Fig. 3. The deduced amino acid sequences of
OXA-23 enzymes were subsequently compared using
BLASTp. The sites of initiation of transcription of the blaOxA-
23 gene were mapped also using real time PCR as the primer
of pre-OXA-23 (Table 1).
Results
Bacteria source and antibiotic susceptibility
The majority of the 59 multiresistant (including imipenem-
resistant) isolates of A. baumannii came from the ICU(52.2%), neurosurgery (22.0%), and respiratory unit (10.2%),
with most samples isolated from sputum (74.6%). In addi-
tion, all of the imipenem-resistant isolates showed high
resistance rates (> 99%) to ampicillin, cefoxitin, ceftazi-
dime, levofloxacin, amikacin, and cefoperazone/sulbactam
in 15 out of 59 isolates, respectively (Fig. 1).
Molecular typing
Fifteen out of 59 clinical isolates were grouped into five
clonal patterns by PFGE. The two major patterns were
pattern A represented by nine isolates and pattern B rep-
resented by three isolates (Fig. 1). Each of the patterns C,
D, and E was represented by a single strain. Four molecular
types, namely patterns A, B, D, and E, were from the ICU.
Strains Ab34 and Ab37, both isolated from venous cannulas
of patients, belonged to patterns B and E, respectively
(Fig. 1). Meanwhile, strains Ab12 and Ab28, both from the
blood of patients in neurosurgery, had patterns C and A,
respectively (Fig. 1). Pattern A clonal lineage was shared by
isolates Ab53, Ab22, Ab40, Ab9, Ab24, Ab31, Ab15, Ab28,
and Ab19 based on PFGE analysis following Tenover et al20
criteria (Fig. 1). According to the details, however, iso-
lates Ab53, Ab22, Ab40, Ab9, and Ab24 were apparently
identical on this basis, but isolates Ab31, Ab15, Ab28, and
Ab19 were closely related to the above. Actually, isolates
Ab31 and Ab15 were apparently identical among them, but
differed in PFGE fragments of isolates Ab53, Ab22, Ab40,
Ab9, and Ab24; simultaneously, isolates Ab28 and Ab19
were apparently identical among them but were different
with PFGE fragments of isolates Ab31 or Ab15. Conse-
quently, they were obviously of different subtypes of
pattern A between isolate Ab28 or Ab19 and isolate Ab31 or
Ab15, in the study.
Table 1 The primers used in the study
Primer name Nucleotide sequence (50/30) Location Reference
PreOXA-23 F ACCTTTAGGGATTCTTTTA blaOxA-23 gene, forward external primer This study
PreOXA-23 R GGCTTAGAGCATTACCATA blaOxA-23 gene, reverse external primer This study
OXA-23 F GGAATTCCATGAATAAATATTTTACTTGC blaOxA-23 gene, forward primer 31
OXA-23 R CGGGATCCCGTTAAATAATATTCAGGTC blaOxA-23 gene, reverse primer 31
OXA23-like F GATGTGTCATAGTATTCGTCG blaOxA-23-like gene, forward primer This study
OXA23-like R TCACAACAACTAAAAGCACTG blaOxA-23-like gene, reverse primer This study
ATPase R GCTTCATCCAGAAGCGTCCGG ATPase gene, reverse primer 34
ISAba1 F ATGCAGCGCTTCTTTGCCAGG tnpA gene of ISAba1, forward primer 34
ISAba1 R AATGATTGGTGACAATGAAG tnpA gene of ISAba1, reverse primer 34
ISAba1-ext F AAGCACTTGATGGGCAAGGC tnpA of ISAba1, forward external primer 30
ISAba4 F ATTTGAACCCATCTATTGGC tnpA gene of ISAba4, forward primer 30
ISAba4 R ACTCTCATATTTTTTCTTGG tnpA gene of ISAba4, reverse primer 30
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blaOxA-23 genes in the A. baumannii clinical isolates
under study
Different genetic structures harboring blaOxA-23 genes were
identified in the A. baumannii isolates under study by
cloning BamHI- or SacI-digested DNA fragments in plasmid
pBKCMV and selecting E. coli transformants bearing blaOxA-
23 genes in amoxicillin-containing solid media. Further
sequence analysis of different clones allowed the identifi-
cation of five different genetic structures in which blaOxA-23
genes were present (Figs. 1 and 2). These were transposons
Tn2006, Tn2008, Tn2007, ISAba1-blaOxA-23-AMP-acid ligase
gene, and ISAba1-blaOxA-23 (Fig. 2). The A. baumannii iso-
lates in which these structures were identified are depicted
in Fig. 1. As seen in this figure, the ISAba1-blaOxA-23
arrangement was the most frequently found (10/15 iso-
lates: Ab31, 22, 40, 9, 14, 24, 41, 5, 17, and 19). Tn2008 was
found in two isolates (Ab12 and Ab18), Tn2006 in Ab34,
Tn2007 in Ab37, and ISAba1-blaOxA-23-AMP-acid ligase gene
in Ab53.IS-derived hybrid promoters enhancing blaOxA-23
expression
Using BLASTp analysis, although the blaOxA-23-like amino acid
sequence was approximately 99.9% identical to that of
blaOxA-23 with a difference at site 104 (K104X), however, the
later experiment proved that blaOxA-23-like was identified
with blaOxA-23. ISAba1 is an insertion sequence located up-
stream of blaampC and blaOxA-51-like genes in A. baumannii
associated with overexpression of these genes.25,26 As seen
in Fig. 3, in isolates Ab31, 22, 40, 9, and 17 we found that
an ISAba1 insertion upstream of the blaOxA-23 gene gener-
ated a hybrid promoter (-35 sequence, TTAGAA; -10
sequence, TTATTT) identical to that identified previously26
that directs expression of this gene. Moreover, we also
found in strain Ab37 an ISAba4 insertion upstream of the
blaOxA-23 gene, also generating a hybrid promoter directing
expression of this gene. In this case, the þ1 transcription
start was located 31 bp upstream of the blaOxA-23 start
codon, and inside ISAba4 IRL. The identified -35 sequence
(TAACTA) and -10 (TTTCTT) promoter sequences whichwere separated by 17 bp (Fig. 3) were identical to those
described previously by other authors.26Discussion
In this study, the 59 non-repetitive pan-resistant (including
imipenem-resistant) isolates of A. baumannii were from the
ICU unit (52.2%) and neurosurgery (22.0%). Fifteen out of 59
clinical isolates were grouped into five clonal patterns by
PFGE: the two major patterns were pattern A (9 isolates)
and pattern B (3 isolates); patterns A, B, D, and E were from
the ICU unit (8 isolates) and pattern C was from the respi-
ratory unit (1 isolate). It was suggested that pattern A might
be prevalent in our hospital, and pattern B happened to
appear in the ICU unit of our hospital. However, further
investigation showed that pattern B also appeared in the
neurosurgery and respiratory units in latter experiments.
Carbapenems have the most extended antimicrobial
spectrum of antibacterial drug among all the b-lactams.
However, reports of carbapenem-resistance have been
increasing, especially in P. aeruginosa and A. baumannii.15
A limited number of antimicrobial agents, including poly-
myxin, sulbactam, and minocycline, maintain a high activ-
ity against OXA-23-producing A. baumannii.10 In particular,
sulbactam has a direct antimicrobial and synergistic effect
with ampicillin against A. baumannii.27
In silico analyses of GenBank databases and personal
observations have indicated that an ISAba1 element, which
belongs to the IS4 family, is constantly identified upstream
of blaOxA-23, regardless of the geographical origin of the
isolate. In addition, an ISAba4 element, which belongs to
the IS982 family, has been identified recently in A. bau-
mannii clinical isolates from France and Algeria.28 The
presence of these IS elements upstream of b-lactamase
genes suggests that they may play a role in blaOxA-23
expression by providing strong hybrid promoter sequences,
and perhaps participate in the acquisition of carbapenem
resistance.1,28
This study demonstrated that transposons Tn2006,
Tn2007, and Tn2008, as well as genetic structures ISAba1-
blaOxA-23-AMP and ISAba1-blaOxA-23 were present in the
clinical strains of A. baumannii studied here. There is an
association between the presence of these b-lactamase-
Figure 2. Schematic representation of the different genetic structures harboring blaOxA-23 genes found in the clinical Acineto-
bacter baumannii isolates studied: (A) transposon Tn2006, reconstructed from two overlapping DNA fragments of approximately
3.4 kbp and 5.4 kbp derived from BamHI and SacI digestion, respectively, of Ab34 DNA and cloned into recombinant plasmids
pAB34B and pAB34S; (B) transposon Tn2008, present in an approximately 7.3 kbp fragment derived from BamHI digestion of either
Ab12 or Ab28 DNA cloned into plasmid pAB12B or pAB28B; (C) transpose Tn2007, present in an approximately 7.3 kbp fragment
derived from BamHI digestion of Ab37 DNA and cloned into plasmid pAB37B; (D) ISAba1-blaOxA-23-AMP acid ligase gene, present in an
approximately 7.3 kbp fragment derived from BamHI digestion of Ab53 DNA and cloned into plasmid pAB53B; (E) ISAba1-blaOxA-23,
present in approximately 7.3 kbp fragments derived from BamHI digestion of DNA obtained from isolates Ab31, Ab22, Ab40, Ab9,
Ab14, Ab24, Ab41, Ab5, Ab17, or Ab19, and cloned into plasmids generally designated pAB. The BamHI (gagctc) and SacI (ggatcc)
restriction sites are indicated. The boundaries of the different transposons are suggested by duplication of target sites likely
generated by the transposition event: Tn2006 (attcgcg), Tn2007 (taatata), and Tn2008 (tgtcgtgt). Deduced open reading frames orf
1 and orf 2 of unknown function are indicated. ATPaseZ putative AAA ATPase gene; DEAD helicaseZ putative DEAD (Asp-Glu-Ala-
Asp) helicase gene; AMP-acid ligase Z AMP-acid ligase gene.
288 D. Wang et al.containing genetic elements and the increased MIC for
imipenem, implying higher drug-resistance levels.
Increased resistance to imipenem suggests that clinical
isolates may contain one or more of the above transposons
and structures. We hypothesize that carbapenem-
hydrolyzing class D b-lactamase genes, belonging to the
blaOxA-23, serve as the actual resistance genes in the study.
An ISAba4 element was identified in the upstream region
of a blaOxA-23 gene in A. baumannii isolate Ab37. This ISAba4
element belongs to the IS982 family, is 975 bp in length,
possesses two 18 bp IRs, and encodes a 292 amino acid
putative transposase. No target site duplication was
observed on either end of ISAba4. PCR mapping by different
sets of primers did not detect any extra copy of ISAba4
downstream of the blaOxA-23 gene. Instead, a predicted AAA
ATPase gene truncated at its 50 terminus is located down-
stream of the blaOxA-23 gene. Detailed analysis of the
truncation site identified a 7 bp sequence with an AT-rich
content (TAATATA) at the extremity of the IRR of ISAba4
(Fig. 2), which most likely represented a transposition
process mediated by ISAba4 that occurred at the origin of
acquisition of the blaOxA-23 gene. This potential transposon,
termed Tn2007, is 2471 bp long and included ISAba4 andblaOxA-23 genes. The ISAba4-mediated mobilization process
may be based on a one-ended transposition mechanism.
This is unlike what has been observed for ISEcp1, which uses
a wide range of DNA sequences such as that of IRR, which
are not absolutely random.24,26,27 These data were consis-
tent with previous findings.26
The Tn2006 insertion isolated from isolate Ab34
occurred inside a gene encoding a putative sulfonamide
resistance protein sharing 89% amino acid identity to a
protein identified in A. baumannii AYE (accession
no.CAJ31116). Sequence analysis of strain Ab34 revealed a
2445 bp sequence containing the blaOxA-23 gene, as well as
part of a putative AAA ATPase gene,29 and part of a putative
DEAD helicase gene.26 These two latter genes were trun-
cated at the exact same position, suggesting that a
recombination event had occurred.26 Simultaneously,
ISAba1 has been shown to be very prevalent in A. baumannii
and might be “customized” for that species.30 It was
described as an ISAba1-based putative composite trans-
poson in a previous reference,26 and it was also proved to
be identical in isolate Ab34 (Fig. 2A).
Tn2008, identified from isolate Ab12 or Ab28, was the
major vehicle carrying blaOxA-23 and had been inserted into
Figure 3. Promoter structures for expression of the blaOxA-23 in Acinetobacter baumannii strains: (A) the genetic structure of a
plasmid in the representative strain Ab31, with insertion sequence ISAba1 and promoter elements located upstream of the blaOxA-23
gene, and it is of the same structures for strains Ab22, Ab40, Ab9, and Ab17; (B) the structure of a plasmid found in strain Ab37,
with insertion sequence ISAba4 and promoter elements located upstream of the blaOxA-23 gene. The þ1 initiation sites of tran-
scription are shown in bold and underlined, while the promoter sequences are boxed. The ATG start codons of blaOxA-23 are shown in
bold. The left IRL of ISAba1 and ISAba4 elements are shaded.
blaOxA-23-like and blaOxA-23 gene regions 289three different AT-rich locations (Fig. 2B). It is likely that
this 16-bp sequence at the left end of Tn2008 served as IRL
of ISAba1. A single copy of ISAba1 could transpose blaOxA-23
and ATPase with itself by recognizing IRL as a new left
boundary. The 16 bp sequence resembled the inverted
repeat of ISAba1, suggesting that ISAba1might have utilized
an alternative boundary to mobilize blaOxA-23.
16 ISAba1
seems to be quite an important factor of genetic plasticity
in A. baumannii,30 and may facilitate the creation of
composite transposons.31 Together with our study that
ISAba1 could be considered widespread in A. baumannii and
a previous report,32 this could suggest that blaOxA-23 origi-
nated from an Acinetobacter species (A. radioresistens).
However, in recent studies33e35 the genetic backgrounds of
this enzyme were characterized, supporting its horizontal
acquisition. It could also be hypothesized that the Tn2008
putative composite transposon might have been formed in
A. baumannii after a previous acquisition process not
related to ISAba1.
To our knowledge, the genetic cluster ISAba1-blaOxA-23-
AMP was the first to be identified in isolate Ab53 in the
study. Its structure is similar to that of strain AcKOU1,36 but
with slight differences: the left side of structure ISAba1-
blaOxA-23 lacks a H
þ symporter gene, and the right side
contains the full-length AMP-acid ligase gene. Meanwhile,
our study also expresses that the ISAba1-blaOxA-23 arrange-
ment can be found in A. baumannii clonal lineages, namely
patterns A, B, and D; Tn2008 can be found in clonal line-
ages, namely patterns A and C, and one group B or E isolate
harbors Tn2006 or Tn2007. These findings probably suggest
that different clones of A. baumannii might be widespread
with the majority of ISAba1-blaOxA-23 clonal lineages in our
hospital.
The corresponding promoter structures for the blaOxA-23
gene in strains Ab31, 22, 40, 9, and 17, were made up of a
-35 sequence (TTAGAA) and the -10 sequence (TTATTT ),
with a 16 bp spacer distance between them using bioin-
formatics procedures. These results agreed with previous
work on ISAba1,26 but were not consistent with findings
from other studies describing a 17 bp spacer region37 and a
-10 promoter sequence of “TATTTC”. Further studies are
needed to investigate the nature of these inconsistencies.
Although all the strains were recovered from patients,
drug-resistant bacteria are also found in hospital spots such
as bed sheets, desks, floors, and cisterns. Numerous studies
have shown that the hospital environment was a preferred
habitat for A. baumannii isolates. A. baumannii appears to
have unique characteristics among nosocomial Gram-negative bacteria with enhanced environmental persis-
tence.1 Our current findings warrant more extensive in-
vestigations into the occurrence of drug resistant bacteria.Conflicts of interest
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